About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT02739932

Adolescent Mental Health: Canadian Psychiatric Risk and Outcome Study

The primary study aims are to determine the clinical, behavioural and social predictors of SMI development in youth, and to investigate whether neuroimaging can distinguish youth who will develop SMI ...

Lead sponsor: University of Calgary•2 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University of Calgary

Collaborators

Brain Canada
Sunnybrook Health Sciences Centre

Age

12 - 25 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Participants will understand and sign an informed consent (or assent for minors) document in English.

Exclusion Criteria

•meet criteria for current or lifetime Axis I bipolar or psychotic disorder (other Axis I disorders will not be exclusionary as they may be precursors to mood or psychotic disorders);
•IQ \< 70;
•past or current history of a significant central nervous system disorder or serious medical disorder; and
•current pharmacological treatment that would be considered as an adequate trial of treatment for a SMI.

Related studies

Research on the Efficacy and Safety of Targeted Suprachiasmatic Nucleus Electrical Stimulation for Improving Metabolic Disorders in Patients With Stable Bipolar Disorder Comorbid With Obesity

NCT07589647 · Bipolar Disorder (BD)

RECRUITINGPhase 2

Correcting Circadian Rhythms to Breakthrough in Bipolar Disorder

NCT06226025 · Bipolar Disorder, Delayed Sleep-Wake Phase Disorder

RECRUITINGPhase 3

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

NCT07227454 · Depressive Disorder, Major

RECRUITINGPhase 3

Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients

NCT06860958 · Depressive Disorder, Major

RECRUITINGPhase 3

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

NCT07140913 · Mania, Bipolar Disorder

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 24, 2022Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment243

Start dateMar 2015

Last updatedMay 24, 2022

Condition

Psychotic Disorders Depressive Disorder, Major Bipolar Disorder

Locations shown

Mathison Centre for Research and Education, University of Calgary

Calgary, Alberta

Sunnybrook Health Sciences Centre

Toronto, Ontario

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 24, 2022Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions